Seek Returns

AZN vs. RDY: AstraZeneca vs. Dr. Reddy's Laboratories Stock Comparison

How do AstraZeneca (AZN) and Dr. Reddy's Laboratories (RDY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

AstraZeneca (AZN) and Dr. Reddy's Laboratories (RDY) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.

Both AstraZeneca (AZN) and Dr. Reddy's Laboratories (RDY) trade as ADRs — their core financials are comparable, but keep FX, depositary-program fees, and dividend withholding in view for each.

Company profile comparison for AstraZeneca (AZN) and Dr. Reddy's Laboratories (RDY)
Profile ItemAZNRDY
NameAstraZeneca PLC American Depositary SharesDr. Reddy's Laboratories Ltd. ADR
Country/RegionUnited KingdomIndia
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticalsPharmaceuticals
GICS Sub-IndustryPharmaceuticalsPharmaceuticals
Market Capitalization289.14 billion USD12.43 billion USD
CurrencyUSDUSD
ExchangeNasdaqNYSE
Listing DateMay 12, 1993April 11, 2001
Security TypeADRADR

Price Performance

Cumulative Growth

AZN
RDY
GSPC
Loading price history…
AstraZeneca (AZN) vs. Dr. Reddy's Laboratories (RDY), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for AstraZeneca (AZN) and Dr. Reddy's Laboratories (RDY). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for AstraZeneca (AZN) and Dr. Reddy's Laboratories (RDY). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for AstraZeneca (AZN) and Dr. Reddy's Laboratories (RDY)
MetricAZNRDY
Total Return (1Y)12.64%12.49%
Total Return (3Y, Annualized)15.75%5.76%
Total Return (5Y, Annualized)10.63%4.06%

Risk Profile

Drawdown History

AZN
RDY
GSPC
Loading price history…
AstraZeneca (AZN) vs. Dr. Reddy's Laboratories (RDY), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for AstraZeneca (AZN) and Dr. Reddy's Laboratories (RDY). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for AstraZeneca (AZN) and Dr. Reddy's Laboratories (RDY)
MetricAZNRDY
Volatility (1Y, Annualized)28.21%27.06%
Beta (5Y)0.220.30
Max Drawdown (5Y)-27.87%-32.01%
Avg. Volume (3M)3.14M2.89M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
AZN and RDY are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for AstraZeneca (AZN) and Dr. Reddy's Laboratories (RDY)
MetricAZNRDY
Sharpe Ratio (1Y)0.300.30
Sortino Ratio (1Y)0.440.43

Profitability

ROE (TTM)

Both AstraZeneca (AZN) at 22.57% and Dr. Reddy's Laboratories (RDY) at 7.34% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

22.57%

Max
109.18%
AZN
22.57%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

RDY

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.34%

Max
109.18%
RDY
7.34%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
AstraZeneca (AZN) vs. Dr. Reddy's Laboratories (RDY): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

For every dollar of sales, both AstraZeneca (AZN) at 17.68% and Dr. Reddy's Laboratories (RDY) at 8.49% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

17.68%

Max
18.05%
AZN
17.68%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

RDY

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.49%

Max
18.05%
RDY
8.49%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
AstraZeneca (AZN) vs. Dr. Reddy's Laboratories (RDY): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

AstraZeneca (AZN) at 29.57% operates in the top operating margin quartile, ahead of Dr. Reddy's Laboratories (RDY) at 14.73%, which runs around its industry’s norm.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

29.57%

Max
83.12%
AZN
29.57%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

RDY

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.73%

Max
83.12%
Q3
14.77%
RDY
14.73%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
AstraZeneca (AZN) vs. Dr. Reddy's Laboratories (RDY): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for AstraZeneca (AZN) and Dr. Reddy's Laboratories (RDY)
MetricAZNRDY
ROE (TTM)22.57%7.34%
ROA (TTM)8.59%3.37%
Net Margin (TTM)17.68%8.49%
Operating Margin (TTM)29.57%14.73%
Gross Margin (TTM)81.78%49.49%

Growth

Revenue Growth

Both AstraZeneca (AZN) at 8.63% and Dr. Reddy's Laboratories (RDY) at 3.19% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
AstraZeneca (AZN) vs. Dr. Reddy's Laboratories (RDY): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both AstraZeneca (AZN) at 45.33% and Dr. Reddy's Laboratories (RDY) at -24.14% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Loading chart…
AstraZeneca (AZN) vs. Dr. Reddy's Laboratories (RDY): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for AstraZeneca (AZN) and Dr. Reddy's Laboratories (RDY)
MetricAZNRDY
Revenue Growth (YoY)8.63%3.19%
Revenue Growth (3Y CAGR)9.82%10.96%
EPS Growth (YoY)45.33%-24.14%
EPS Growth (3Y CAGR)45.80%-1.72%

Financial Strength

Current Ratio (MRQ)

Both AstraZeneca (AZN) at 1.01 and Dr. Reddy's Laboratories (RDY) at 1.93 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.01

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
AZN
1.01
Min
0.10

RDY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.93

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
RDY
1.93
Min
0.10
Loading chart…
AstraZeneca (AZN) vs. Dr. Reddy's Laboratories (RDY): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Dr. Reddy's Laboratories (RDY) at 0.19 carries an industry-typical debt-to-equity mix, while AstraZeneca (AZN) at 0.66 uses more debt funding than most peers.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.66

Max
1.42
AZN
0.66
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00

RDY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.19

Max
1.42
Q3
0.65
RDY
0.19
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
AstraZeneca (AZN) vs. Dr. Reddy's Laboratories (RDY): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for AstraZeneca (AZN) and Dr. Reddy's Laboratories (RDY)
MetricAZNRDY
Current Ratio (MRQ)1.011.93
Debt / Equity (MRQ)0.660.19
Net Debt / EBITDA1.23-0.08

Dividends

Dividend Yield (TTM)

Both AstraZeneca (AZN) at 1.73% and Dr. Reddy's Laboratories (RDY) at 55.06% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.73%

AZN
1.73%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

RDY

Pharmaceuticals, Biotechnology & Life Sciences industry group

55.06%

RDY
55.06%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
AstraZeneca (AZN) vs. Dr. Reddy's Laboratories (RDY): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Both AstraZeneca (AZN) at 45.38% and Dr. Reddy's Laboratories (RDY) at 22.72% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

45.38%

AZN
45.38%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

RDY

Pharmaceuticals, Biotechnology & Life Sciences industry group

22.72%

RDY
22.72%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
AstraZeneca (AZN) vs. Dr. Reddy's Laboratories (RDY): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for AstraZeneca (AZN) and Dr. Reddy's Laboratories (RDY)
MetricAZNRDY
Dividend Yield (TTM)1.73%55.06%
Dividend Payout Ratio (TTM)45.38%22.72%

Valuation

P/E Ratio (TTM)

Both AstraZeneca (AZN) at 26.37 and Dr. Reddy's Laboratories (RDY) at 41.42 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.37

Max
85.34
Q3
43.46
Median
26.69
AZN
26.37
Q1
13.30
Min
0.07

RDY

Pharmaceuticals, Biotechnology & Life Sciences industry group

41.42

Max
85.34
Q3
43.46
RDY
41.42
Median
26.69
Q1
13.30
Min
0.07
Loading chart…
AstraZeneca (AZN) vs. Dr. Reddy's Laboratories (RDY): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

Dr. Reddy's Laboratories (RDY) at 0.04 sits in the cheaper P/S ratio quartile while AstraZeneca (AZN) at 4.63 prices around its industry’s middle — RDY costs less per dollar of sales, though read it alongside growth and margins.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.63

Max
58.18
Q3
25.77
Median
7.30
AZN
4.63
Q1
3.01
Min
0.01

RDY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.04

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
RDY
0.04
Min
0.01
Loading chart…
AstraZeneca (AZN) vs. Dr. Reddy's Laboratories (RDY): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

AstraZeneca (AZN) at 5.59 sits near its industry’s typical P/B ratio, while Dr. Reddy's Laboratories (RDY) at 18.16 prices above its benchmark range — RDY looks rich relative to book.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.59

Max
13.53
Q3
6.54
AZN
5.59
Median
3.25
Q1
1.69
Min
-5.59

RDY

Pharmaceuticals, Biotechnology & Life Sciences industry group

18.16

RDY
18.16
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
AstraZeneca (AZN) vs. Dr. Reddy's Laboratories (RDY): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for AstraZeneca (AZN) and Dr. Reddy's Laboratories (RDY)
MetricAZNRDY
P/E Ratio (TTM)26.3741.42
P/S Ratio (TTM)4.630.04
P/B Ratio (MRQ)5.5918.16
Free Cash Flow Yield (TTM)1.95%-53.03%